FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W119150346> ?p ?o ?g. }

• W119150346 abstract "Abstract Aims: To review the outcome of allogeneic stem cell transplantation (SCT) in imatinib refractory chronic myeloid leukaemia (CML). Methods: Outcomes of all allogeneic transplants performed after January 2001 for CML at our institution were retrospectively reviewed. Imatinib-refractory CML was defined as either lack of any cytogenetic response (CGR) after at least 6mths of imatinib, loss of CGR or progression to a more advanced disease stage (accelerated or blast phase) during imatinib therapy. Using the EBMT risk score (Lancet1998; 352: 1087), transplant outcomes for imatinib refractory CML were compared with all other CML transplants performed during the same time period. Survival analysis was performed using the Kaplan-Meier product-limit and comparison of survival data via the log-rank test. Results: Of 31 allogeneic transplants (19M; 12F) performed for CML, 12 had been performed for imatinib refractory CML (no CGR to imatinib n=3; loss of CGR n=3; progression to AP n=3; progression to BC n=3), 5 in patients with imatinib responsive CML, and 14 in patients never exposed to imatinib. Median age at SCT was 40yrs (range 19–63yrs). Donor source included HLA-matched unrelated donors in 14 cases, HLA-identical siblings in 16 and other matched family donors in 1. Conditioning regimens included Cy/TBI (20 cases), Bu/Cy (8 cases), Flu/Mel (2 cases) and Flu/Cy (1 case); CsA + MTX was used as standard GVHD prophylaxis. EBMT risk scores were 1 (4 cases), 2 (6 cases), 3 (8 cases), 4 (5 cases), 5 (3 cases) and 6 (5 cases). At median follow-up post-SCT of 37mths (range 6–64mths), median PFS and OS are not reached; at 2yrs PFS, EFS and OS are 81%, 58% and 61% respectively. For patients with EBMT risk scores of 1–2 versus 3–4 versus 5–6, OS at 2 yrs post-SCT is 80%, 62% and 38% respectively (p=0.03). Based on EBMT risk score, no significant differences in PFS, EFS or OS were observed when comparing SCT for imatinib-refractory versus imatinib-responsive / imatinib-naïve CML. Conclusion: Our experience suggests that survival post-SCT for imatinib-refractory CML is similar to SCT for imatinib-responsive / imatinib-naïve CML. The EBMT risk score appears to remain useful in predicting survival post-SCT in imatinib-refractory CML." @default.
• W119150346 created "2016-06-24" @default.
• W119150346 creator A5005383371 @default.
• W119150346 creator A5019767352 @default.
• W119150346 creator A5020529745 @default.
• W119150346 creator A5024269557 @default.
• W119150346 creator A5024939376 @default.
• W119150346 creator A5028552390 @default.
• W119150346 creator A5051174375 @default.
• W119150346 creator A5064029394 @default.
• W119150346 creator A5077736042 @default.
• W119150346 date "2006-11-16" @default.
• W119150346 modified "2023-10-16" @default.
• W119150346 title "Allogeneic Transplant Outcomes in Imatinib-Refractory Chronic Myeloid Leukaemia (CML) Are Similar to Transplant Outcomes in Imatinib-Responsive/Imatinib-Naïve CML and Appear To Be Predicted by the EBMT Risk Score." @default.
• W119150346 doi "https://doi.org/10.1182/blood.v108.11.3155.3155" @default.
• W119150346 hasPublicationYear "2006" @default.
• W119150346 type Work @default.
• W119150346 sameAs 119150346 @default.
• W119150346 citedByCount "0" @default.
• W119150346 crossrefType "journal-article" @default.
• W119150346 hasAuthorship W119150346A5005383371 @default.
• W119150346 hasAuthorship W119150346A5019767352 @default.
• W119150346 hasAuthorship W119150346A5020529745 @default.
• W119150346 hasAuthorship W119150346A5024269557 @default.
• W119150346 hasAuthorship W119150346A5024939376 @default.
• W119150346 hasAuthorship W119150346A5028552390 @default.
• W119150346 hasAuthorship W119150346A5051174375 @default.
• W119150346 hasAuthorship W119150346A5064029394 @default.
• W119150346 hasAuthorship W119150346A5077736042 @default.
• W119150346 hasConcept C121332964 @default.
• W119150346 hasConcept C126322002 @default.
• W119150346 hasConcept C141071460 @default.
• W119150346 hasConcept C142424586 @default.
• W119150346 hasConcept C143998085 @default.
• W119150346 hasConcept C2777583451 @default.
• W119150346 hasConcept C2778729363 @default.
• W119150346 hasConcept C2911091166 @default.
• W119150346 hasConcept C3019892230 @default.
• W119150346 hasConcept C71924100 @default.
• W119150346 hasConcept C87355193 @default.
• W119150346 hasConcept C90924648 @default.
• W119150346 hasConceptScore W119150346C121332964 @default.
• W119150346 hasConceptScore W119150346C126322002 @default.
• W119150346 hasConceptScore W119150346C141071460 @default.
• W119150346 hasConceptScore W119150346C142424586 @default.
• W119150346 hasConceptScore W119150346C143998085 @default.
• W119150346 hasConceptScore W119150346C2777583451 @default.
• W119150346 hasConceptScore W119150346C2778729363 @default.
• W119150346 hasConceptScore W119150346C2911091166 @default.
• W119150346 hasConceptScore W119150346C3019892230 @default.
• W119150346 hasConceptScore W119150346C71924100 @default.
• W119150346 hasConceptScore W119150346C87355193 @default.
• W119150346 hasConceptScore W119150346C90924648 @default.
• W119150346 hasLocation W1191503461 @default.
• W119150346 hasOpenAccess W119150346 @default.
• W119150346 hasPrimaryLocation W1191503461 @default.
• W119150346 hasRelatedWork W1980324865 @default.
• W119150346 hasRelatedWork W1984450483 @default.
• W119150346 hasRelatedWork W2040429996 @default.
• W119150346 hasRelatedWork W2050873057 @default.
• W119150346 hasRelatedWork W2351846431 @default.
• W119150346 hasRelatedWork W2384189294 @default.
• W119150346 hasRelatedWork W2565130792 @default.
• W119150346 hasRelatedWork W2943298525 @default.
• W119150346 hasRelatedWork W2974945014 @default.
• W119150346 hasRelatedWork W2050540976 @default.
• W119150346 isParatext "false" @default.
• W119150346 isRetracted "false" @default.
• W119150346 magId "119150346" @default.
• W119150346 workType "article" @default.